Spark Therapeutics (ONCE) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research note issued to investors on Thursday morning. Cantor Fitzgerald currently has a $80.00 price target on the biotechnology company’s stock, down from their previous price target of $103.00.

A number of other research analysts have also weighed in on the company. William Blair restated a buy rating on shares of Spark Therapeutics in a report on Friday, September 21st. Raymond James restated a buy rating on shares of Spark Therapeutics in a report on Friday, September 21st. Guggenheim started coverage on Spark Therapeutics in a report on Tuesday, October 9th. They issued a buy rating and a $70.00 target price on the stock. Zacks Investment Research lowered Spark Therapeutics from a buy rating to a hold rating in a report on Saturday, October 13th. Finally, B. Riley upgraded Spark Therapeutics from a neutral rating to a buy rating and raised their target price for the company from $68.00 to $71.00 in a report on Wednesday, November 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $65.20.

ONCE stock opened at $43.36 on Thursday. Spark Therapeutics has a twelve month low of $34.53 and a twelve month high of $96.59. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.36 and a current ratio of 10.71. The company has a market capitalization of $1.67 billion, a PE ratio of -5.68 and a beta of 1.98.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.18%. The company had revenue of $10.70 million during the quarter, compared to the consensus estimate of $27.44 million. During the same quarter in the prior year, the business earned ($1.90) EPS. The firm’s revenue for the quarter was up 463.2% compared to the same quarter last year. Equities research analysts anticipate that Spark Therapeutics will post -1.53 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. Partner Investment Management L.P. lifted its holdings in Spark Therapeutics by 27.9% during the second quarter. Partner Investment Management L.P. now owns 11,511 shares of the biotechnology company’s stock worth $953,000 after acquiring an additional 2,513 shares during the period. MetLife Investment Advisors LLC raised its stake in shares of Spark Therapeutics by 14.9% in the second quarter. MetLife Investment Advisors LLC now owns 14,454 shares of the biotechnology company’s stock valued at $1,196,000 after buying an additional 1,869 shares during the period. BlackRock Inc. raised its stake in shares of Spark Therapeutics by 8.7% in the second quarter. BlackRock Inc. now owns 2,869,232 shares of the biotechnology company’s stock valued at $237,459,000 after buying an additional 229,786 shares during the period. Morgan Stanley raised its stake in shares of Spark Therapeutics by 18.7% in the second quarter. Morgan Stanley now owns 462,121 shares of the biotechnology company’s stock valued at $38,244,000 after buying an additional 72,744 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of Spark Therapeutics by 38.3% in the third quarter. Alliancebernstein L.P. now owns 531,184 shares of the biotechnology company’s stock valued at $28,976,000 after buying an additional 147,158 shares during the period.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Further Reading: Marijuana Stocks Investing Considerations

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply